New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
04:55 EDTMDVN, MDVN, MDVN, MYGN, MYGN, MYGNAmerican Society of Clinical Oncology to hold symposium
ASCO 2014 Genitourinary (GU) Cancers Symposium is being held in San Francisco on January 30-February 1.
News For MDVN;MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
07:09 EDTMYGNMyriad Genetics presents myChoice HRD companion diagnostic test data at ASCO
Subscribe for More Information
07:06 EDTMYGNMyriad Genetics presents myRisk Hereditary Cancer data at ASCO
Myriad Genetics announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting. The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.
07:06 EDTMDVNAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 28, 2015
09:00 EDTMDVNPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
10:28 EDTMYGNMAC updates positive for NanoString, Myriad, Invitae, QIAGEN, says Leerink
Leerink said that coverage updates posted yesterday by Medicare Administrative Contractors were favorable for NanoString (NSTG), Myriad Genetics (MYGN), Invitae (NVTA) and QIAGEN (QGEN). The firm has Outperform ratings on NanoString and Invitae and Market Perform rating on the other two stocks listed.
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
07:09 EDTMYGNMyriad Genetics presents clinical data for Prolaris test
Myriad Genetics presented clinical data for its Prolaris test at the 2015 American Urological Association, or AUA, Annual Meeting being held May 15-19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians improve care for men diagnosed with prostate cancer. In this pioneering study, Myriad presented important new clinical validation data that establishes an active surveillance, or AS, threshold for men with localized prostate cancer. Specifically, the AS threshold is a composite of the Prolaris test score and clinicopathologic features. In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality. The results showed that at the AS threshold, the predicted 10-year survival rate of prostate cancer patients was 97%. Conversely, there was a three percent risk of 10-year, prostate-specific mortality. Importantly, however, there were no observed prostate cancer-specific deaths over 10 years among men whose scores fell below the AS threshold. Additionally, a separate analysis of 4,218 patients was performed to determine what percentage of patients who were clinically tested with Prolaris would be candidates for active surveillance based on the validated AS threshold. Of this commercial cohort, 36% qualified for active surveillance based on their clinical features alone. However, when the Prolaris test was added to the clinical risk assessment, 60% of these patients fell below the AS threshold, representing a significant increase in the total number of candidates who may be eligible for active surveillance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use